Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 5
2016 6
2017 7
2018 10
2019 15
2020 9
2021 5
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
The INGENIOUS trial: Impact of pharmacogenetic testing on adverse events in a pragmatic clinical trial.
Eadon MT, Rosenman MB, Zhang P, Fulton CR, Callaghan JT, Holmes AM, Levy KD, Gupta SK, Haas DM, Vuppalanchi R, Benson EA, Kreutz RP, Tillman EM, Shugg T, Pierson RC, Gufford BT, Pratt VM, Zang Y, Desta Z, Dexter PR, Skaar TC. Eadon MT, et al. Pharmacogenomics J. 2023 Nov;23(6):169-177. doi: 10.1038/s41397-023-00315-w. Epub 2023 Sep 9. Pharmacogenomics J. 2023. PMID: 37689822 Clinical Trial.
Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention.
Cavallari LH, Limdi NA, Beitelshees AL, Lee JC, Duarte JD, Franchi F, Tuteja S, Giri J, Empey PE, Kreutz RP, Skaar TC, Allen JM, Coons JC, Gong Y, McDonough CW, Stevenson JM, Thomas CD, Johnson JA, Stouffer GA, Angiolillo DJ, Lee CR; IGNITE Network. Cavallari LH, et al. Clin Pharmacol Ther. 2023 Mar;113(3):615-623. doi: 10.1002/cpt.2776. Epub 2022 Nov 19. Clin Pharmacol Ther. 2023. PMID: 36306392 Free PMC article.
CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention in Diverse Clinical Settings.
Beitelshees AL, Thomas CD, Empey PE, Stouffer GA, Angiolillo DJ, Franchi F, Tuteja S, Limdi NA, Lee JC, Duarte JD, Kreutz RP, Skaar TC, Coons JC, Giri J, McDonough CW, Rowland R, Stevenson JM, Thai T, Vesely MR, Wellen JT, Johnson JA, Winterstein AG, Cavallari LH, Lee CR; Implementing Genomics in Practice (IGNITE) Network Pharmacogenetics Working Group. Beitelshees AL, et al. J Am Heart Assoc. 2022 Feb 15;11(4):e024159. doi: 10.1161/JAHA.121.024159. Epub 2022 Feb 12. J Am Heart Assoc. 2022. PMID: 35156424 Free PMC article.
Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX: A GeT-RM Collaborative Project.
Pratt VM, Turner A, Broeckel U, Dawson DB, Gaedigk A, Lynnes TC, Medeiros EB, Moyer AM, Requesens D, Vetrini F, Kalman LV. Pratt VM, et al. J Mol Diagn. 2021 Aug;23(8):952-958. doi: 10.1016/j.jmoldx.2021.04.012. Epub 2021 May 19. J Mol Diagn. 2021. PMID: 34020041 Free PMC article.
Expanding evidence leads to new pharmacogenomics payer coverage.
Empey PE, Pratt VM, Hoffman JM, Caudle KE, Klein TE. Empey PE, et al. Genet Med. 2021 May;23(5):830-832. doi: 10.1038/s41436-021-01117-w. Epub 2021 Feb 24. Genet Med. 2021. PMID: 33627827 Free PMC article. No abstract available.
Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.
Hicks JK, El Rouby N, Ong HH, Schildcrout JS, Ramsey LB, Shi Y, Anne Tang L, Aquilante CL, Beitelshees AL, Blake KV, Cimino JJ, Davis BH, Empey PE, Kao DP, Lemkin DL, Limdi NA, P Lipori G, Rosenman MB, Skaar TC, Teal E, Tuteja S, Wiley LK, Williams H, Winterstein AG, Van Driest SL, Cavallari LH, Peterson JF; IGNITE Pharmacogenetics Working Group. Hicks JK, et al. Clin Pharmacol Ther. 2021 Jul;110(1):179-188. doi: 10.1002/cpt.2161. Epub 2021 Feb 16. Clin Pharmacol Ther. 2021. PMID: 33428770 Free PMC article.
Prescribing Prevalence of Medications With Potential Genotype-Guided Dosing in Pediatric Patients.
Ramsey LB, Ong HH, Schildcrout JS, Shi Y, Tang LA, Hicks JK, El Rouby N, Cavallari LH, Tuteja S, Aquilante CL, Beitelshees AL, Lemkin DL, Blake KV, Williams H, Cimino JJ, Davis BH, Limdi NA, Empey PE, Horvat CM, Kao DP, Lipori GP, Rosenman MB, Skaar TC, Teal E, Winterstein AG, Owusu Obeng A, Salyakina D, Gupta A, Gruber J, McCafferty-Fernandez J, Bishop JR, Rivers Z, Benner A, Tamraz B, Long-Boyle J, Peterson JF, Van Driest SL; IGNITE Pharmacogenetics Working Group. Ramsey LB, et al. JAMA Netw Open. 2020 Dec 1;3(12):e2029411. doi: 10.1001/jamanetworkopen.2020.29411. JAMA Netw Open. 2020. PMID: 33315113 Free PMC article.
Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee CR, Thomas CD, Beitelshees AL, Tuteja S, Empey PE, Lee JC, Limdi NA, Duarte JD, Skaar TC, Chen Y, Cook KJ, Coons JC, Dillon C, Franchi F, Giri J, Gong Y, Kreutz RP, McDonough CW, Stevenson JM, Weck KE, Angiolillo DJ, Johnson JA, Stouffer GA, Cavallari LH; IGNITE Network Pharmacogenetics Working Group. Lee CR, et al. Clin Pharmacol Ther. 2021 Mar;109(3):705-715. doi: 10.1002/cpt.2039. Epub 2020 Oct 2. Clin Pharmacol Ther. 2021. PMID: 32897581 Free PMC article.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing.
Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, Uppugunduri CRS, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS, Furuta T. Lima JJ, et al. Clin Pharmacol Ther. 2021 Jun;109(6):1417-1423. doi: 10.1002/cpt.2015. Epub 2020 Sep 20. Clin Pharmacol Ther. 2021. PMID: 32770672 Free PMC article.
51 results